An iPSP is due before the trial starts, not the NDA

The deadline is a meeting, not a filing

PREA, as amended by FDASIA, requires a sponsor to submit an initial pediatric study plan within 60 days after the End-of-Phase-2 meeting with FDA — or at another time agreed with the agency — rather than alongside the marketing application the pediatric studies are meant to support. That timing puts the obligation years ahead of the submission most regulatory teams build their project plans around. A sponsor that treats the iPSP as part of the NDA package, due whenever the rest of the application is due, has already missed the statutory trigger, because the trigger is a meeting that happens during development, not a filing that happens at the end of it.

No End-of-Phase-2 meeting doesn't mean no deadline

Not every program holds a formal EOP2 meeting, and FDA's guidance on pediatric study plans doesn't treat that as an exemption. A sponsor that skips the meeting is still expected to submit the iPSP as early as practicable, and before starting any Phase 3 study or combined Phase 2/3 study. The deadline moves with the development path a sponsor actually takes, rather than disappearing when that path skips the specific meeting the statute uses as its default anchor. A program planning straight from Phase 2 into a combined pivotal study has less runway to prepare the iPSP than the 60-day EOP2 clock suggests, not more.

FDA's own review clock runs on top of the sponsor's

Submitting the iPSP on time starts a negotiation, not an approval. FDA reviews the submitted plan and responds, the sponsor has its own window to address that response, and the agency then confirms the agreed plan in a further round — a sequence that can run well past the sponsor's original 60-day submission deadline before the plan is actually settled. A sponsor who meets the submission deadline but assumes the plan is final the moment it's filed is tracking the wrong milestone; the iPSP isn't done until FDA has agreed to it, and that agreement is a separate clock layered on top of the one PREA sets for submission.

Oncology extended the same clock to a different trigger

The RACE for Children Act folded certain cancer drugs into the same iPSP framework on a different test than the rest of PREA uses. Where PREA's base requirement turns on whether a drug treats a disease that also occurs in children, RACE-covered applications can trigger the iPSP requirement based on the molecular target a drug is directed at, independent of the specific adult indication being studied. The submission timing doesn't change — the same End-of-Phase-2 anchor applies — but the question a regulatory team has to ask earlier does: not just “does this disease occur in children,” but “is this target relevant to a pediatric cancer,” a question that has to be answered before the EOP2 meeting even happens if the iPSP clock is going to start on time.

Missing it doesn't just make the plan late

PREA's leverage point isn't the iPSP deadline itself — it's the marketing application that follows. A sponsor that reaches its NDA or BLA without an agreed iPSP, an approved deferral, or a waiver on file risks a refuse-to-file action on the application itself, not a late note attached to an otherwise-complete package. That makes the iPSP one of the few pediatric-development documents where a scheduling miss years earlier can block the door on the application the whole program was built to support, which is a different kind of risk than the studies themselves ever carry on their own.

Where this meets the file

A pediatric-program tracker that keys its milestones to the End-of-Phase-2 meeting date, with the iPSP deadline calculated from that date rather than from the planned application date, is previewed in the launch catalog alongside this week's other clinical-development templates. If your program tracks that handoff differently, the shelf takes that correction directly.